•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A02534 Summary:

BILL NOA02534
 
SAME ASSAME AS S04501
 
SPONSORMcDonald
 
COSPNSRBlumencranz, Simone, Seawright, Ramos, Lavine, Lunsford, Bronson, Zaccaro, Colton, Meeks, Davila, Angelino, Bendett, Levenberg, Bologna, Gray, McMahon, Wieder, Steck, Kay, Jacobson, Brown K, Buttenschon, Romero, Shimsky, Smullen, Morinello, Reyes, Brabenec, Santabarbara, Manktelow, Palmesano, McDonough, Novakhov, Maher, Woerner, Stirpe, Gallahan, Lee, Berger, Pheffer Amato, Chludzinski, Slater, Giglio, Clark
 
MLTSPNSR
 
Amd §6801, Ed L
 
Provides for the initiation of treatment for COVID-19, influenza, and pharyngitis resulting from a Group A streptococcal infection by a licensed pharmacist in certain circumstances.
Go to top

A02534 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          2534
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                    January 17, 2025
                                       ___________
 
        Introduced  by M. of A. McDONALD, BLUMENCRANZ, SIMONE, SEAWRIGHT, RAMOS,
          LAVINE, LUNSFORD, BRONSON, ZACCARO, COLTON, MEEKS,  DAVILA,  ANGELINO,
          BENDETT, LEVENBERG -- read once and referred to the Committee on High-
          er Education
 
        AN  ACT  to  amend  the  education law, in relation to the definition of
          practice of pharmacy; and providing for the repeal of such  provisions
          upon expiration thereof
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Section 6801 of the education law is amended  by  adding  a
     2  new subdivision 7-a to read as follows:
     3    7-a.  (a)  A  licensed pharmacist may initiate treatment for COVID-19,
     4  influenza, and  pharyngitis  resulting  from  a  Group  A  streptococcal
     5  infection  upon a positive test result conducted pursuant to subdivision
     6  seven of this section. Such treatment shall be provided  pursuant  to  a
     7  statewide  protocol developed by the department of health. Such protocol
     8  shall address issues including but not limited to patient safety, record
     9  keeping, referral for treatment and continuity of care,  case  reporting
    10  to the patient's primary care or other health care providers. The proto-
    11  col  shall  also  include  procedures  for appropriate referrals for any
    12  patient that requires additional treatment  or  experiences  an  adverse
    13  reaction to the treatment authorized pursuant to this subdivision.
    14    (b)  A  pharmacist initiating treatment under this protocol shall at a
    15  minimum: (i) inquire of each patient whether the patient has  a  primary
    16  care  provider  or other health care provider that the patient regularly
    17  sees; and (ii) maintain and regularly update a  list  of  local  primary
    18  care  providers  including those located in the applicable zip code area
    19  and adjacent zip code areas of the pharmacy. This list shall be provided
    20  to each patient who indicates that the patient does not have  a  primary
    21  care provider.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD03393-01-5

        A. 2534                             2
 
     1    (c) The department of health shall produce, maintain, and periodically
     2  update  a  list  of primary care providers on its website, in searchable
     3  form that shall include relevant zip codes of the  providers.  The  list
     4  developed by the department of health shall identify preferred providers
     5  who  have achieved recognition as a patient centered medical home (PCMH)
     6  or other similar designation and a description of what such  designation
     7  means.  The  list  shall  include federally qualified health centers and
     8  other providers who serve Medicaid, low-income and  uninsured  patients,
     9  and  people with disabilities and shall identify cultural and linguistic
    10  capabilities when available.
    11    (d) A pharmacist shall retain a record of the test result  and  treat-
    12  ment  as  part  of  the  patient record and shall at a minimum provide a
    13  report of the test result and  treatment  to  the  patient's  designated
    14  physician, physician's assistant or nurse practitioner, unless otherwise
    15  directed by the patient.
    16    §  2.  This  act shall take effect immediately and shall expire and be
    17  deemed repealed April 1, 2028.
Go to top